The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and activity of autologous T cells with enhanced NY-ESO-1–specific T-cell receptor (GSK3377794) in HLA-a*02+ previously-treated and -untreated patients with advanced metastatic/unresectable synovial sarcoma: A master protocol study design (IGNYTE-ESO).
 
Sandra P. D'Angelo
Consulting or Advisory Role - Adaptimmune; Amgen; EMD Serono; GlaxoSmithKline; Immune design; Incyte; Merck; Nektar
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Deciphera (Inst); EMD Serono (Inst); Incyte (Inst); Merck (Inst); Nektar (Inst)
Travel, Accommodations, Expenses - Adaptimmune; EMD Serono; Nektar
 
Jean-Yves Blay
Leadership - Innate Pharma
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD; PharmaMar; Roche
Consulting or Advisory Role - Bayer; Blueprint Medicines; Deciphera; Pharmamar; Roche
Research Funding - Bayer (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pharmamar (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Roche
 
Warren Allen Chow
Consulting or Advisory Role - GlaxoSmithKline
Speakers' Bureau - Novartis
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline
Other Relationship - Advenchen Laboratories; Via Oncology
 
George D. Demetri
Leadership - Blueprint Medicines; Merrimack; Translate BIO
Stock and Other Ownership Interests - Bessor Pharma; Blueprint Medicines; Caprion/HistoGeneX; Caris Life Sciences; Champions Oncology; Erasca, Inc; G1 Therapeutics; Merrimack; Relay Therapeutics; Translate BIO
Consulting or Advisory Role - Acrivon Therapeutics; Adaptimmune; Arsenal Capital; Bayer; Blueprint Medicines; Caprion/HistoGeneX; Caris Life Sciences; Daiichi Sankyo; EMD Serono; Epizyme; G1 Therapeutics; ICON Clinical Research; Ignyta; Janssen Oncology; Loxo; Medscape; Mirati Therapeutics; MJH Associates; Novartis; Pfizer; PharmaMar; Polaris; Relay Therapeutics; Roche/Genentech; Sanofi; WIRB-Copernicus Group; ZIOPHARM Oncology
Research Funding - Abbvie (Inst); AbbVie (Inst); Adaptimmune (Inst); Bayer (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Janssen Oncology (Inst); Loxo (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Patent on use of imatinib for GIST, receive minor royalty payment from Dana-Farber after license between Dana-Farber and Novartis
Expert Testimony - Epizyme
 
Fiona Thistlethwaite
Consulting or Advisory Role - Achilles Therapeutics; Bristol-Myers Squibb; Evelo Therapeutics; GlaxoSmithKline; Octimet (Inst); Zelluna
Research Funding - 3-V Biosciences (Inst); Actuate Therapeutics (Inst); Adaptimmune (Inst); Adaptimmune (Inst); Agalimmune (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); BerGenBio (Inst); Blueprint Medicines (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Carrick Therapeutics (Inst); CytomX Therapeutics (Inst); Eisai (Inst); GenMab (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Immutep (Inst); Incyte (Inst); Janssen (Inst); kinex (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Millenium Pharamceuticals (Inst); MSD (Inst); Novartis (Inst); Octimet (Inst); Orion (Inst); Pfizer (Inst); Redx Pharma (Inst); Roche (Inst); Roche (Inst); Sierra Oncology (Inst); Synthon (Inst); Takeda (Inst); Tarveda Therapeutics (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline; Zelluna
Other Relationship - iMatch
 
Shiraj Sen
Consulting or Advisory Role - Daiichi Sankyo (Inst)
Research Funding - BioAtla (Inst); Exelixis (Inst); Jacobio (Inst); Loxo (Inst)
 
Albiruni Ryan Abdul Razak
Honoraria - Boehringer Ingelheim
Consulting or Advisory Role - Adaptimmune; Boehringer Ingelheim; Lilly; Merck
Research Funding - Abbvie; Adaptimmune; Amgen; Blueprint Medicines; Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; CASI Pharmaceuticals; Deciphera; GlaxoSmithKline; Iterion Therapeutics; Karyopharm Therapeutics; Lilly; MedImmune; Merck; Novartis; Pfizer; Roche/Genentech
 
John B. A. G. Haanen
Stock and Other Ownership Interests - Neogen
Consulting or Advisory Role - Amgen; AstraZeneca; Ault International Medical Management; Bayer; Bristol-Myers Squibb; Celsius Therapeutics; Gadeta; GlaxoSmithKline; Immunocore; Merck Serono; MSD; Neogene; Neon Therapeutics; Novartis; Pfizer; Roche; Sanofi; Seagen
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); MSD (Inst); Neon Therapeutics (Inst)
 
Jonathan Christopher Noujaim
Honoraria - Bayer; Lilly
Consulting or Advisory Role - Bayer
 
Melissa Lynne Johnson
Consulting or Advisory Role - Abbvie (Inst); Achilles Therapeutics (Inst); Association of Community Cancer Centers (ACCC) (Inst); Astellas Pharma (I); AstraZeneca (Inst); Atreca (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Guardant Health (Inst); Incyte (Inst); Janssen Oncology (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Otsuka (I); Pfizer (Inst); Ribon Therapeutics (Inst); Sanofi (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Adaptimmune (Inst); Amgen (Inst); Apexigen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Atreca (Inst); BeiGene (Inst); Birdie (Inst); Boehringer Ingelheim (Inst); Checkpoint Therapeutics (Inst); Corvus Pharmaceuticals (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dynavax Technologies (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Genmab (Inst); Genocea Biosciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Guardant Health (Inst); Hengrui Pharmaceutical (Inst); Immunocore (Inst); Incyte (Inst); Janssen (Inst); Jounce Therapeutics (Inst); Kadmon (Inst); Lilly (Inst); Loxo (Inst); Lycera (Inst); Merck (Inst); Mirati Therapeutics (Inst); Neovia Oncology (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst); Regeneron (Inst); Ribon Therapeutics (Inst); Sanofi (Inst); Shattuck Labs (Inst); Stem CentRx (Inst); Syndax (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); TCR2 Therapeutics (Inst); University of Michigan (Inst); WindMIL (Inst)
Travel, Accommodations, Expenses - Abbvie; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Daiichi Sankyo; EMD Serono; Exelixis; Genentech; Incyte; Janssen Oncology; Lilly; Merck; Novartis; Pfizer; Sanofi; Sysmex; Vapotherm
 
Theodore Willis Laetsch
Consulting or Advisory Role - Bayer; Lilly; Loxo; Novartis
Research Funding - Abbvie (Inst); Amgen (Inst); Atara Biotherapeutics (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Jubilant Pharmaceuticals (Inst); Lilly (Inst); Loxo (Inst); Novartis (Inst); Novella Clinical (Inst); Pfizer (Inst); SERVIER (Inst)
 
Victoria L. Chiou
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Patents, Royalties, Other Intellectual Property - MedImmune
 
Laura Pearce
Employment - GlaxoSmithKline
Consulting or Advisory Role - GlaxoSmithKline
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Personal Genome Diagnostics (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline
Other Relationship - Canadian Cancer Trials Group; Cancer Research Institute
 
Thomas H. Faitg
Employment - Adaptimmune; GlaxoSmithKline
Stock and Other Ownership Interests - Adaptimmune; GlaxoSmithKline
Research Funding - GlaxoSmithKline
 
Ran Ji
Employment - GlaxoSmithKline
 
Laura A. Johnson
Employment - GlaxoSmithKline
Patents, Royalties, Other Intellectual Property - Novartis
 
Aiman M. Shalabi
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
Travel, Accommodations, Expenses - GlaxoSmithKline
 
Katherine Anne Thornton
Consulting or Advisory Role - Adaptimmune; Agios; Lilly; Macrogenics; More Health
Expert Testimony - Kilcoyne & Nesbitt
 
Crystal Mackall
Stock and Other Ownership Interests - Alimera Sciences; Apricity Health; Lyell Immunopharma; Vor Biopharma
Consulting or Advisory Role - Alimera Sciences; Apricity Health; Bryology; Lyell Immunopharma; Nektar; NeoImmuneTech; PACT Pharma; TPG; Vor Biopharma
Patents, Royalties, Other Intellectual Property - I am an inventor on numerous patents related to chimeric antigen receptor therapeutics and received royalties from NIH for the CD22-CAR patent licensed to Juno therapeutics.
Travel, Accommodations, Expenses - Nektar; NeoImmuneTech; Roche
Other Relationship - Lyell Immunopharma
 
Brian Andrew Van Tine
Leadership - Polaris
Consulting or Advisory Role - Adaptimmune; Bayer; Caris Life Sciences; CytRx Corporation; Daiichi Sankyo; EMD Serono; Epizyme; GlaxoSmithKline; Immune Design; Johnson & Johnson; Lilly/ImClone; Novartis; Pfizer; Plexxikon; Threshold Pharmaceuticals
Speakers' Bureau - Adaptimmune; Caris Life Sciences; GlaxoSmithKline; Johnson & Johnson; Lilly; Novartis
Research Funding - GlaxoSmithKline; Merck; Pfizer; TRACON Pharma
Patents, Royalties, Other Intellectual Property - Patent on ALEXT3102; Patent on the use of ME1 as a biomarker
Travel, Accommodations, Expenses - Adaptimmune; Advenchen Laboratories; Lilly